EG 006

Drug Profile

EG 006

Alternative Names: EG006; Vitor

Latest Information Update: 16 Sep 2010

Price : $50

At a glance

  • Originator Unknown
  • Developer Ark Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cachexia

Most Recent Events

  • 09 Sep 2010 Discontinued - Phase-II/III for Cachexia in USA (PO)
  • 09 Sep 2010 Discontinued - Phase-III for Cachexia in Europe (PO)
  • 28 Jan 2010 Suspended - Phase-II/III for Cachexia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top